| Literature DB >> 24319457 |
Malgorzata Sawicka-Żukowska1, Maryna Krawczuk-Rybak, Katarzyna Muszynska-Roslan, Anna Panasiuk, Eryk Latoch, Jerzy Konstantynowicz.
Abstract
Childhood cancer survivors are in augmented risk for developing obesity. For many factors leptin and leptin receptor gene polymorphism play an important role in the development and metabolism not only of fat, but also, bone tissue. The aim of the analysis was to find the relationships between Q223R, leptin levels, and anthropometric parameters. Patients and Methods. In the study 74 cancer survivors participated (ALL n = 64, lymphomas n = 10), and the control group consisted of 51 healthy peers. Leptin blood concentration was determined by ELISA method. To estimate leptin receptor gene polymorphism, RFLP method was used. Bone mineral density (BMD) and content (BMC), fat, and lean tissue measurements were obtained by DXA. Results. We found no correlations between serum leptin concentrations and anthropometric parameters nor BMD. Serum leptin concentrations were significantly lower in the group of cancer survivors compared to controls; however, in those overweight from examined group we found leptin levels higher than those in nonoverweight. Genotype Q223R was not associated with higher leptin levels, BMI, BMD, body fat or lean tissue. Conclusion. To our knowledge, this is the first report describing the relationship between BMD and Q223R polymorphism in childhood cancer survivors. Further analysis, based on a larger group of patients, is needed to confirm these findings.Entities:
Year: 2013 PMID: 24319457 PMCID: PMC3834979 DOI: 10.1155/2013/805312
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Characteristics of the examined and control group.
| Examined group | Control group |
| |||
|---|---|---|---|---|---|
|
|
| ||||
|
| % |
| % | ||
| Gender | |||||
| Girls | 32 | 43.24 | 17 | 33.33 | 0.265 |
| Boys | 42 | 56.76 | 34 | 66.67 | |
| Diagnosis | |||||
| Acute leukemias | 64 | ||||
| Lymphomas | 10 | ||||
| Average age at the beginning of the treatment (years) | 6.292 ± 3.685 | ||||
| Average age at a time of the end of the treatment (years) | 8.857 ± 3.537 | ||||
| Average age at the time of the analysis (years) | 15.473 ± 2.643 | 14.77 ± 3.643 | 0.881 | ||
Distribution of Q223R polymorphism.
| Examined group | Control group | ||||
|---|---|---|---|---|---|
| Genotype |
|
|
| ||
|
| % |
| % | ||
| GG | 21 | 28.38 | 20 | 39.22 | 0.205 |
| Girls | 6 | 28.57 | 9 | 45.00 | 0.275 |
| Boys | 15 | 71.43 | 11 | 55.00 | |
| Leukemias | 19 | 90.48 | |||
| Lymphomas | 2 | 9.52 | |||
| GA | 42 | 56.76 | 24 | 47.06 | 0.286 |
| Girls | 22 | 52.38 | 5 | 20.83 | 0.012 |
| Boys | 20 | 47.62 | 19 | 79.17 | |
| Leukemias | 35 | 83.33 | |||
| Lymphomas | 7 | 16.67 | |||
| AA | 11 | 14.86 | 7 | 13.72 | 0.858 |
| Girls | 4 | 36.36 | 3 | 42.86 | 0.783 |
| Boys | 7 | 63.64 | 4 | 57.14 | |
| Leukemias | 10 | 90.91 | |||
| Lymphomas | 1 | 9.09 | |||
Values of the anthropometric and densitometric parameters in the whole group, according to Q223R LEPR genotype.
| Whole group | GG | AG | AA |
|
| |
|---|---|---|---|---|---|---|
| WHR1 | 0.8606 | 0.8489 | 0.8672 | 0.8615 | 0.092 | 0.912 |
| Height SDS | −0.1974 | −0.3383 | −0.2210 | 0.1633 | 1.407 | 0.260 |
| BMI SDS2 | 0.556 | 0.360 | 0.434 | 1.357 | 1.054 | 0.360 |
| BMD total SDS3 | −0.0132 | 0.5292 | −0.2691 | −0.1386 | 0.880 | 0.423 |
| BMD spine SDS4 | −0.2610 | 0.0383 | −0.4227 | −0.2657 | 0.800 | 0.457 |
| LEAN SDS5 | 0.1502 | 0.0180 | 0.3396 | −0.2183 | 0.281 | 0.756 |
| FAT SDS6 | 4.7943 | 6.0488 | 4.1250 | 4.7471 | 0.265 | 0.769 |
| BMC SDS7 | 0.3244 | 0.6000 | 0.1923 | 0.2671 | 0.441 | 0.647 |
|
|
|
|
1∗ P value between genotype GG and AG.
2∗ P value between genotype AA and AG.
3∗ P value between genotype GG and AA.
1WHR: waist to hip ratio.
2BMI SDS: Body Mass Index Standard Deviation Score.
3BMD total SDS: total Bone Mineral Density Standard Deviation Score.
4BMD spine SDS: Bone Mineral Density in the lumbar area Standard Deviation Score.
5LEAN SDS: Lean Mass Standard Deviation Score.
6FAT SDS: Fat Mass Standard Deviation Score.
7BMC SDS: Bone Mineral Content Standard Deviation Score.
Figure 1Serum leptin levels in the whole group, overweight/obese and nonoverweight/obese subjects (P < 0.01), and patients who receive and who did not received cranial radiotherapy (P < 0.01). CRT (+)—patients who received cranial radiotherapy; CRT (−)—patients who did not receive cranial radiotherapy.
Leptin concentration in the whole examined and control groups, accordingly to Q223R LEPR genotype.
| LEPTIN | Examined group | Control group |
| ||
|---|---|---|---|---|---|
| Value (ng/mL) | SD ± | Value | SD ± | Sig | |
| Whole group | 6.640 | 7.699 | 14.484 | 19.280 | 0.013 |
| GG | 3.78789 | 3.764 | 7.528 | 8.963 | 0.021 |
| AG | 6.63087 | 8.347 | 7.608 | 13.400 | 0.67 |
| AA | 7.83218 | 7.810 | 1.696 | 19.949 | 0.031 |
*P value as a comparison in leptin value between examined group and control group.
Correlation between anthropometric and densitometric parameters in the whole group.
| Whole group | Leptin levels | WHR | Height SDS | BMI SDS | BMDt SDS | BMDs SDS | FAT SDS | LEAN SDS | BMC SDS | |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Leptin levels | Correlation coefficient | 0.55 | 0.263 | 0.152 | 0.444 | 0.748 | 0.586 | 0.409 | 0.686 | |
| WHR | −0.079 | 0.64 | 0.024 | 0.927 | 0.259 | 0.613 | 0.309 | 0.309 | ||
| Height SDS | −0.207 | −0.08 | 0.406 | 0.033 | 0.003 | 0.286 | 0 | 0 | ||
| BMI SDS | 0.264 |
| 0.133 | 0.003 | 0.001 | 0 | 0.041 | 0 | ||
| BMDt SDS | 0.143 | −0.414 |
|
| 0.023 | 0.006 | 0.006 | 0.023 | ||
| BMDs SDS | −0.06 | 0.142 |
|
|
| 0.005 | 0 | 0 | ||
| FAT SDS | 0.102 | 0.272 | 0.171 |
|
|
| 0.282 | 0 | ||
| LEAN SDS | −0.154 | −0.262 |
|
|
|
| 0.172 | 0 | ||
| BMC SDS | 0.076 | −0.262 |
|
|
|
|
|
| ||
Correlation between anthropometric and densitometric parameters in the group with LEPR gene genotype GA.
| GA | Leptin levels | WHR | Height SDS | BMI SDS | BMDt SDS | BMDs SDS | FAT SDS | LEAN SDS | BMC SDS | |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Leptin levels | Correlation coefficient | 0.696 | 0.321 | 0.094 | 0.963 | 0.309 | 0.305 | 0.66 | 0.926 | |
| WHR | −0.08 | 0.977 | 0.483 | 0.781 | 0.474 | 0.323 | 0.582 | 0.782 | ||
| Height SDS | −0.256 | 0.007 | 0.871 | 0.032 | 0.003 | 0.799 | 0 | 0 | ||
| BMI SDS | 0.42 | 0.166 | 0.037 | 0.004 | 0.032 | 0 | 0.369 | 0.011 | ||
| BMDt SDS | 0.012 | 0.066 |
|
| 0 | 0.072 | 0.003 | 0 | ||
| BMDs SDS | −0.262 | −0.17 |
|
|
| 0.223 | 0 | 0 | ||
| FAT SDS | 0.265 | 0.233 | 0.058 |
| 0.391 | 0.27 | 0.974 | 0.109 | ||
| LEAN SDS | −0.115 | −0.131 |
| 0.201 |
|
| 0.007 | 0 | ||
| BMC SDS | −0.025 | −0.066 |
|
|
|
| 0.351 |
| ||
Correlation between anthropometric and densitometric parameters in the group with LEPR gene genotype AA.
| AA | Leptin levels | WHR | Height SDS | BMI SDS | BMDt SDS | BMDs SDS | FAT SDS | LEAN SDS | BMC SDS | |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Leptin levels | Correlation coefficient | 0.76 | 0.188 | 1 | 0.873 | 1 | 1 | 0.873 | 0.624 | |
| WHR | 0.143 | 0.957 | 0.125 | 0.208 | 0.544 | 0.872 | 0.872 | 0.156 | ||
| Height SDS | 0.7 | 0.029 | 0.09 | 0.094 | 0.148 | 0.094 | 0.036 | 0.036 | ||
| BMI SDS | 0 | 0.696 | 0.685 | 0.006 | 0.006 | 0.09 | 0.078 | 0.001 | ||
| BMDt SDS | 0.1 | 0.6 | 0.679 |
| 0.036 | 0.119 | 0.253 | 0 | ||
| BMDs SDS | 0 | 0.314 | 0.607 |
|
| 0.007 | 0.119 | 0.023 | ||
| FAT SDS | 0 | 0.086 | 0.679 | 0.685 | 0.643 |
| 0.148 | 0.094 | ||
| LEAN SDS | −0.1 | 0.086 |
| 0.703 | 0.5 | 0.643 | 0.607 | 0.119 | ||
| BMC SDS | 0.3 | 0.657 |
|
|
|
| 0.679 | 0.643 | ||
Correlation between anthropometric and densitometric parameters in the group with LEPR gene genotype GG.
| GG | Leptin levels | WHR | Height SDS | BMI SDS | BMDt SDS | BMDs SDS | FAT SDS | LEAN SDS | BMC SDS | |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Leptin levels | Correlation coefficient | 0.762 | 0.242 | 0.932 | 0.308 | 0.937 | 0.356 | 0.332 | 0.831 | |
| WHR | −0.082 | 0.526 | 0.002 | 0.612 | 0.937 | 0.06 | 0.631 | 0.026 | ||
| Height SDS | −0.435 | −0.215 | 0.632 | 0.983 | 0.712 | 0.329 | 0.007 | 0.221 | ||
| BMI SDS | −0.03 |
| 0.154 | 0.983 | 0.762 | 0 | 0.175 | 0.001 | ||
| BMDt SDS | 0.383 | 0.173 | −0.007 | 0.007 | 0.101 | 0.681 | 0.681 | 0.216 | ||
| BMDs SDS | 0.027 | 0.582 | −0.119 | 0.098 | 0.497 | 0.762 | 0.931 | 0.47 | ||
| FAT SDS | −0.35 | 0.582 | 0.309 |
| 0.133 | 0.098 | 0.124 | 0 | ||
| LEAN SDS | −0.367 | 0.164 |
| 0.42 | 0.133 | −0.028 | 0.469 | 0.103 | ||
| BMC SDS | −0.08 |
| 0.381 |
| 0.497 | 0.231 |
| |||
Stepwise forward regression model for BMI value.
| Parameter |
| SD |
|
|
|---|---|---|---|---|
| BMD total SDS | 0.2812 | 0.0955 | 2.9942 |
|
| BMD spine SDS | 0.1854 | 0.1641 | 1.1299 | 0.2488 |
| FAT SDS | 0.1942 | 0.0345 | 5.6162 |
|
Stepwise forward regression model for leptin levels.
| Parameter |
| SD |
|
|
|---|---|---|---|---|
| BMD total SDS | 5216.33 | 893.233 | 5.8398 |
|
| BMD spine SDS | −6526.86 | 1303.73 | −5.006 |
|
| LEAN SDS | −2477.40 | 986.33 | −2.5117 |
|
| GG genotype | 3755.55 | 2014.82 | 1.8639 | 0.0952 |
| Cranial radiotherapy | 2191.25 | 2031.74 | 1.0785 | 0.3088 |